Quratis

Quratis EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Quratis (348080.KQ) as of Oct 16, 2026 is -22.78 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -13.23 B KRW — a change of 72.14% (lower).

EBITDA

-22.78 BKRW

YoY

72.14%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Quratis is 2024 -22.78 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Quratis was 2023 -13.23 B KRW. It decreases by 72.14% lower compared to the previous year.

The Quratis EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
-13.21 B KRW
Jan 1, 2021
-14.21 B KRW
Jan 1, 2023
-13.23 B KRW
Jan 1, 2024
-22.78 B KRW
The Quratis EBITDA history
YEAREBITDAYoY
-22.78 BKRW+72.14%
-13.23 BKRW-6.85%
-14.21 BKRW+7.57%
-13.21 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quratis Stock analysis

What does Quratis do? Quratis Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company went public on June 15, 2023, with its stock listed under the ticker 348080.KQ and ISIN KR734808080003. Quratis focuses on research and development in the pharmaceutical industry, specifically developing medicine and pharmaceutical products. The company is involved in the manufacture and sale of vaccines and peptide nucleic acid complexes. It also provides Cell Penetrating Peptide (CPP) platform services. Quratis is engaged in the development and research of vaccines, including tuberculosis vaccines for adults and adolescents and COVID-19 vaccines. The company has 91 employees and maintains a website at http://quratis.com/. Quratis operates in the biotechnology industry, emphasizing innovation in vaccine development and pharmaceutical research. Its headquarters are located in Seoul, South Korea, and it is active in the development of novel therapeutic solutions for global health challenges. The company's activities span from research to commercialization, with a focus on advancing medical treatments through biotechnology. Quratis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quratis stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Quratis is -22.78 B KRW in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Quratis changed from -13.23 B KRW to -22.78 B KRW, representing a 72.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Quratis since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Quratis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Quratis

All Key Metrics — Quratis